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Histamine and Histamine 
H4 Receptor Promotes 
Osteoclastogenesis in Rheumatoid 
Arthritis
Kyoung-Woon Kim1, Bo-Mi Kim1, Kyung-Ann Lee2, Sang-Heon Lee2, Gary S. Firestein3 &  
Hae-Rim Kim2
Histamine H4 receptor (H4R) has immune-modulatory and chemotaxic effects in various immune 
cells. This study aimed to determine the osteoclastogenic role of H4R in rheumatoid arthritis (RA). 
The concentration of histamine in synovial fluid (SF) and sera in patients with RA was measured 
using ELISA. After RA SF and peripheral blood (PB) CD14+ monocytes were treated with histamine, 
IL-17, IL-21 and IL-22, and a H4R antagonist (JNJ7777120), the gene expression H4R and RANKL 
was determined by real-time PCR. Osteoclastogenesis was assessed by counting TRAP–positive 
multinucleated cells in PB CD14+ monocytes cultured with histamine, Th17 cytokines and JNJ7777120. 
SF and serum concentration of histamine was higher in RA, compared with osteoarthritis and healthy 
controls. The expression of H4R was increased in PB monocytes in RA patients. Histamine, IL-6, IL-17, 
IL-21 and IL-22 induced the expression of H4R in monocytes. Histamine, IL-17, and IL-22 stimulated 
RANKL expression in RA monocytes and JNJ7777120 reduced the RANKL expression. Histamine and 
Th17 cytokines induced the osteoclast differentiation from monocytes and JNJ7777120 decreased 
the osteoclastogenesis. H4R mediates RANKL expression and osteoclast differentiation induced by 
histamine and Th17 cytokines. The blockage of H4R could be a new therapeutic modality for prevention 
of bone destruction in RA.
Rheumatoid arthritis (RA) is a systemic autoimmune disorder, characterized by chronic synovitis of peripheral 
joints, subsequent cartilage and bone destruction followed by joint disability1, 2. Various cellular receptors and 
intracellular signal molecules have been highlighted in RA pathogenesis because the inhibition of their biologic 
function showed significant improvement of clinical symptoms and signs in RA patients3–7.
Histamine is a short-acting biological amine that is widely distributed throughout the human body8–10. The 
role of histamine in the pathogenesis of RA inflammation is largely unknown. A few studies determining hista-
mine has pro-inflammatory or anti-inflammatory role in RA is still controversial. Histamine is present in RA 
blood, synovial tissue, synovial fluid (SF) and articular cartilage11–14. While T cells, macrophages and neutrophils 
synthesize synovial histamine, the main cells producing histamine are mast cells. Mast cells are increased in 
RA synovial tissues and cartilage-pannus junctions15. In RA, chondrocytes produce histamine which stimulates 
the production of prostaglandin E and matrix metalloproteinase (MMP)-1, causing joint damages16–19. These 
results suggest histamine is pro-inflammatory molecule in RA pathogenesis. On the contrary, the injection of 
histamine into mouse knee joints induces no signs of synovitis20. Serum and SF levels of histamine are lower in 
RA patients than in healthy volunteers and the histamine level increases with controlling RA disease activity with 
tumor necrosis factor (TNF)-α inhibitor20. The clinical and laboratory studies for the role of histamine in RA do 
not coincide, but the discordance has not been deduced. Although the role of histamine in RA pathogenesis is 
obscure, in the basis of the pathogenesis and pathology, histamine could be proinflammatory and tissue destruc-
tive molecules in RA.
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The biological function of histamine is mediated through 4 different histamine receptors, histamine H1~H4 
receptors9, 10, 21. They have different unique characteristics in their expression, function, and signal transduction10, 22. 
Histamine H4 receptor (H4R) is a G-protein coupled receptor and it is expressed mainly on various immune 
cells such as mast cells, eosinophils, monocytes, dendritic cells, T cells and natural killer cells23. Previous studies 
suggest H4R has a key role in inflammatory process of RA. H4R is expressed in RA synovial tissues, vessels and 
synovial cells, both macrophage-like and fibroblast-like synoviocytes24–27. In K/BxN serum transfer mice, a H4R 
antagonist, clozapine, protects mice from arthritis symptoms and histological cartilage and bone damage28. In 
collagen-induced arthritis and collagen antibody-induced arthritis models, H4R deficiency and H4R blockage 
ameliorate clinical arthritis, histological damage and number of Th17 cells29, 30. The mechanisms that H4R antago-
nist controls arthritis are reduction of pro-inflammatory cytokines and mediators, nuclear factor NF-κB, MMP-3, 
and a pro-inflammatory receptor, glucocorticoid-induced TNFR-related protein, while H4R antagonist increases 
number of blood CD4+ CD25+ FOXP3+ Treg cells, and the expression of interleukin (IL)-10 and transforming 
growth factor-β29, 30. However, one study shows the gene expression of H4R is decreased in RA synovial tissue 
compared with osteoarthritis, it has negative correlation with MMP-3 and serum levels of anti-cyclic citrullinated 
peptide antibody and C-reactive protein31. So, the role of H4R in RA pathogenesis needs to be clarified.
This study aimed to determine the role of histamine and H4R in osteoclastogenesis of RA. We examined 
the role of histamine on induction of the receptor activator of nuclear factor-κB ligand (RANKL) and osteo-
clast differentiation from its precursors. We also determined the mediation of H4R in the histamine and Th17 
cytokine-induced RANKL expression and osteoclastogenesis. Therefore, we suggest the blockage of H4R could 
be a new therapeutic modality for prevention of bone destruction in RA patients.
Results
SF and serum concentration of histamine in RA patients. The SF and serum concentration of his-
tamine was measured using ELISA kit in 40 patients with RA (18 patients for SF and 19 patients for serum), 
20 patients of osteoarthritis and 19 healthy controls. The clinical characteristics for RA patients who provided 
their SF were as follows; 3 males and 15 females, age 57.1 ± 3.9 years, ESR 50.2 ± 8.6 mm/h, CRP 3.3 ± 0.7 mg/dl, 
and rheumatoid factor 65 ± 20.0 IU/ml. The SF concentration of histamine was higher in RA patients than in 
osteoarthritis patients (20,639 ± 5,824 pg/ml vs 8,872 ± 1,799 pg/ml, P < 0.05, Fig. 1a). The clinical characteris-
tics for RA patients who provided their sera were as follows; 4 males and 15 females, age 55.3 ± 4.0 years, ESR 
55.9 ± 8.7 mm/h, CRP 3.4 ± 0.8 mg/dl, and rheumatoid factor 111.4 ± 27.7 IU/ml. The serum concentration of 
histamine was also higher in RA patients than in healthy controls (11,894 ± 7,786 pg/ml vs 7,490 ± 3,279 pg/ml, 
P < 0.05, Fig. 1b). There was no correlation between the histamine concentration in SF and sera with the clinical 
measures (data not shown).
Basal expression of H4R mRNA in SF and PB CD14+ monocytes of RA patients. The basal 
expression of H4R mRNA in PB monocytes was increased in RA patients, compared with healthy controls 
(P < 0.05, Fig. 2a). However, there was no statistical difference of the H4R mRNA expression in SF monocytes 
between RA and OA patients (Fig. 2b).
The expression of H4R mRNA induced by histamine and inflammatory cytokines in CD14+ 
monocytes. To determine the effective cytokines for induction of H4R expression, CD14+ monocytes from 
PB of RA patients were cultured with histamine and various inflammatory cytokines such as TNF-α, IL-1β, IL-6, 
IL-17, IL-21, IL-22 and IL-23. Histamine, IL-6, IL-17, IL-21 and IL-22 significantly increased the expression 
of H4R (Fig. 3a) in PB monocytes. Especially, the stimulatory effect of IL-21 and IL-22 on the H4R expression 
Figure 1. The synovial fluid (SF) and serum concentration of histamine in RA patients. (a) The SF 
concentration of histamine in RA and osteoarthritis patients was measured using ELISA. (b) The serum 
concentration of histamine in RA patients and healthy controls was measured using ELISA. The data represent 
the mean ± SEM of three independent experiments. *P < 0.05. RA; rheumatoid arthritis, OA; osteoarthritis, 
HC; healthy control.
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was much larger than histamine, so we selected the Th17 cytokines, IL-17, IL-21 and IL-22, as the interesting 
cytokines for further studies. When CD14+ monocytes from PB of RA patients and healthy controls and cul-
tured with various doses of histamine (0–10−4 M), the H4R mRNA expression was increased with maximal effect 
of 10−5 M of histamine (data not shown). In PB and SF monocytes of RA patients, the histamine stimulated H4R 
expression and JNJ7777120, a selective H4R antagonist, tended to reduce the histamine stimulation, however, 
there was no statistical significance (Fig. 3b,c). IL-17, IL-21 and IL-22 increased H4R expression in PB monocytes 
of RA patients and JNJ7777120 reversed IL-17 and IL-22-induced H4R expression (Fig. 3d).
The expression of RANKL mRNA induced by histamine and Th17 cytokines in CD14+ mono-
cytes. The expression of RANKL mRNA of CD14+ monocytes of PB and SF from RA patients was increased 
by histamine and it decreased by JNJ7777120 (Fig. 4a,b). IL-17 and IL-22 stimulated the expression of RANKL in 
PB monocytes and JNJ7777120 reduced the IL-22-induced RANKL expression (Fig. 4c). However, IL-21 did not 
increase RANKL expression.
Histamine-induced osteoclast differentiation in PB monocytes. PB CD14+ monocytes can dif-
ferentiate into osteoclasts when they are cultured with RANKL and M-CSF. To determine the osteoclastogenic 
effect of histamine, CD14+ monocytes isolated from PB were cultured with histamine and M-CSF in the absence 
of RANKL. After 21 days of culture, TRAP+ multinucleated osteoclasts were differentiated in the culture with 
histamine and JNJ7777120 reduced the histamine-induced osteoclastogenesis in osteoclast precursors from RA 
patients and healthy controls (Fig. 5a,b). The gene expression of osteoclast markers, such as TRAP, cathepsin K, 
and MMP-9 was significantly increased with histamine stimulation and decreased with JNJ7777120 (Fig. 5c). 
There was no synergistic or additive effect of histamine and RANKL in osteoclast differentiation (Fig. 5d).
The mediation of H4R in Th17 cytokine-induced osteoclast differentiation. PB CD14+ monocytes 
were cultured with IL-17, IL-21 or IL-22 in the presence of M-CSF. After 21 days of culture, TRAP+ multinucleated 
osteoclasts were differentiated with the stimulation of the three cytokines in a dose dependent manner. JNJ7777120 
reduced the Th17 cytokine-induced osteoclastogenesis in a dose dependent manner (P < 0.001, Fig. 6a–c).
Figure 2. The expression of histamine H4 receptor (H4R) in peripheral blood (PB) and synovial fluid (SF) 
monocytes of patients with rheumatoid arthritis (RA). (a) The basal expression of H4R mRNA in PB CD14+ 
monocytes from 7 RA patients and 4 healthy controls. (b) The basal expression of H4R mRNA in SF monocytes 
from 5 RA patients and 3 osteoarthritis patients. Data were normalized to beta-actin and reported in relative 
expression units. The data represent the mean ± SEM of three independent experiments. *P < 0.05. H4R; 
histamine H4 receptor, RA; rheumatoid arthritis, OA; osteoarthritis, HC; healthy control.
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Discussion
Although H4R is characterized by its unique role in inflammatory, autoimmune and allergic diseases, there are 
still not clear studies for determination of its role in RA pathogenesis32. In this study, we aimed to define the 
role of histamine and its receptor, H4R on the osteoclastogenesis in RA. H4R has a major role in controlling 
inflammation and joint destruction in preclinical animal models28–30 and mast cells and histamine is present in 
Figure 3. The expression of H4R mRNA induced by histamine and inflammatory cytokines. (a) After PB 
monocytes were cultured with 20 ng/ml of TNF-α, IL-1β, IL-6, IL-17, IL-21, IL-22, IL-23 and 10−5 M of 
histamine for 16 h, the expression of H4R mRNA was determined by real-time PCR. (b) After PB CD14+ 
monocytes from 3 RA patients were cultured with 10−5 M of histamine and 10 μM of JNJ7777120, a selective 
H4R antagonist, for 16 h, the expression of H4R mRNA was determined by real-time PCR. (c) After SF CD14+ 
monocytes from 3 RA patients were cultured with 10−5 M of histamine and 10 μM of JNJ7777120 for 16 h, 
the expression of H4R mRNA was determined by real-time PCR. (d) After PB monocytes from 3 RA patients 
were cultured with IL-17, IL-21, IL-22 and 10 μM of JNJ7777120 for 16 h, the expression of H4R mRNA was 
determined by real-time PCR. Data were normalized to beta-actin and reported in relative expression units. 
The data represent the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001. 
H4R; histamine H4 receptor, JNJ; JNJ7777120.
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pannus-bone junction and they increase monocyte recruitment close to bone surface15, 33. On the basis of these 
results, histamine and its receptors could involve in bone destructive process of RA. However, there has not been 
in vitro study for their osteoclastogenic roles using biologic samples from RA patients. We hypothesized hista-
mine could have a role in osteoclastogenesis when it is mediated thorough H4R and the osteoclastogenic effect of 
Th17 cytokines could be mediated through H4R in RA.
For determination of clinical significance of histamine in RA, we measured the histamine concentration in 
RA SF and serum. In RA, SF and serum concentration of histamine was increased, compared with controls. In 
previous studies, there is much lower concentration of histamine in RA SF and sera20, 34, 35. The inconsistency 
between the studies and our study, it is possible that they measured it with different methods such as fluorometric 
method or radioimmunoassay, while we measured histamine concentration using ELISA kit. There are contro-
versial results among the studies for the clinical meaning of histamine in RA. When RA disease activity is divided 
three groups as DAS28, very active group has the highest histamine index (SF histamine concentration/serum 
histamine concentration×100) and inactive group has the lowest histamine index34. However, another study 
shows serum concentration of histamine has negative correlation with CRP and DAS28 score, and after treating 
with infliximab, the serum histamine concentration increases20.
To examine the basal expression of H4R in RA cells, we compared the expression of H4R mRNA in PB and SF 
monocytes between patients with RA, OA and healthy controls. The expression of H4R mRNA was significantly 
higher in RA PB monocytes than in OA PB monocytes, while there was no difference in the expression of H4R 
mRNA between RA and OA SF monocytes. H4R is mainly expressed in bone marrow-originated cells such as 
mast cells, eosinophils, monocytes, and T cells. Our preliminary study showed that PB, but not SF, mononuclear 
cells expressed higher H4R in RA patients than in health controls (data not shown). This result supports blood 
cells express much higher H4R than synovial cells, however, in RA synovial unit, macrophage-like synoviocytes, 
fibroblast-like synoviocytes, chondrocytes and osteoclasts express H4R27. There is lower expression of H4R in RA 
synovial tissues than in OA synovial tissues and the authors explain negative feedback effect of the expression of 
Figure 4. The expression of RANKL mRNA induced by histamine and Th17 cytokines. (a) After PB monocytes 
from 3 RA patients were cultured with 10−5 M of histamine and 10 μM of JNJ7777120 for 16 h, the expression 
of RANKL mRNA was determined by real-time PCR. (b) After SF monocytes from 3 RA patients were cultured 
with 10−5 M of histamine and 10 μM of JNJ7777120 for 16 h, the expression of RANKL mRNA was determined 
by real-time PCR. (c) After PB monocytes from 3 RA patients were cultured with IL-17, IL-21, IL-22 and 
10 μM of JNJ7777120 for 16 h, the expression of RANKL mRNA was determined by real-time PCR. Data were 
normalized to beta-actin and reported in relative expression units. The data represent the mean ± SEM of three 
independent experiments. *P < 0.05, and ***P < 0.001. H4R; histamine H4 receptor, JNJ; JNJ7777120.
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Figure 5. Histamine-induced osteoclast differentiation in PB monocytes and the inhibitory effect of H4R 
antagonist in RANKL-induced osteoclastogenesis. (a) CD14+ monocytes isolated from PB of HC were cultured 
with 0–10−5 M of histamine and 10 μM of JNJ7777120 in the presence of 25 ng/ml of M-CSF. After 21 days 
of culturing, TRAP-positive multinucleated cells were counted. The figures represent one of 3 independent 
experiments. (b) CD14+ monocytes isolated from PB of 3 RA patients were cultured with 0–10−5 M of histamine 
and 10 μM of JNJ7777120 in the presence of 25 ng/ml of M-CSF. After 21 days of culturing, TRAP-positive 
multinucleated cells were counted. The figures represent one of three independent experiments. (c) CD14+ 
monocytes were cultured with 0–10−5 M of histamine and 10 μM of JNJ7777120 in the presence of 25 ng/ml 
M-CSF and the mRNA expression of osteoclast markers such as TRAP, RANK, cathepsin K, MMP-9 and CTR 
was determined using real-time PCR. (d) CD14+ monocytes were cultured with 10 ng/ml of RANKL, 10−5 M 
histamine, and RANKL with histamine in the presence of 25 ng/ml of M-CSF. After 21 days of culturing, TRAP-
positive multinucleated cells were counted. The figures represent one of three independent experiments. The 
figures represent one of three independent experiments. The data represent the mean ± SEM of three independent 
experiments. **P < 0.01 and ***P < 0.001. TRAP; tartrate-resistant acid phosphatase, JNJ; JNJ7777120, RANK; 
receptor activator of nuclear factor-κB, MMP-9; matrix metalloproteinase-9, CTR; calcitonin receptor.
www.nature.com/scientificreports/
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Figure 6. Th17 cytokine-induced osteoclast differentiation in monocytes and the effect of H4R antagonist. (a) 
PB monocytes isolated were cultured with 10–20 ng/ml of IL-17 and 1–10 μM of JNJ7777120 in the presence of 
25 ng/ml of M-CSF. After 21 days of culturing, TRAP-positive multinucleated cells were counted and the mRNA 
expression of osteoclast markers such as TRAP, RANK, cathepsin K, MMP-9 and CTR was determined using 
real-time PCR. (b) PB monocytes were cultured with 10–20 ng/ml of IL-21 and 1–10 μM of JNJ7777120 in the 
presence of 25 ng/ml of M-CSF. After 21 days of culturing, TRAP-positive multinucleated cells were counted 
and the mRNA expression of osteoclast markers such as TRAP, RANK, cathepsin K, MMP-9 and CTR was 
determined using real-time PCR. (c) PB monocytes were cultured with 10–20 ng/ml of IL-22 and 1–10 μM of 
JNJ7777120 in the presence of 25 ng/ml of M-CSF. After 21 days of culturing, TRAP-positive multinucleated 
cells were counted and the mRNA expression of osteoclast markers such as TRAP, RANK, cathepsin K, MMP-9 
and CTR was determined using real-time PCR. The figures represent one of three independent experiments. 
The data represent the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001. 
TRAP; tartrate-resistant acid phosphatase, JNJ; JNJ7777120, RANK; receptor activator of nuclear factor-κB, 
MMP-9; matrix metalloproteinase-9, CTR; calcitonin receptor.
www.nature.com/scientificreports/
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H4R by repeated stimulation of the receptor31. However, because the concentration of histamine is lower in RA 
SF20, it is possible that H4R could have systemic effect rather than localized effect in the joints, mediating by other 
inflammatory molecules, not by histamine.
Previous study shows histamine promotes osteoclastogenesis through H1R and H2R, however, there has been 
no study for the role of histamine and H4R on osteoclastogenesis33. The major mechanism of osteoclastognesis in 
RA synovium is the upregulation of RANKL in synovial and immune cells and the activation of synovial osteo-
clast precursors36, 37. In our study, histamine up-regulated RANKL and H4R expression in RA PB and SF mono-
cytes, and this effect was inhibited by JNJ7777120, a selective H4R antagonist. This result suggests histamine 
induces RANKL expression in both peripheral circulation and local joints, which has a potential for activation 
of osteoclast precursors and H4R mediates the histamine-induced RANKL expression. Although the pattern of 
histamine-induced RANKL expression was similar in PB monocytes of healthy volunteers and RA patients and 
SF monocytes of RA patients, there was the strongest effect of histamine-induced RANKL expression PB mono-
cytes from healthy volunteers. Because histamine level is lower in RA patients20, 38 and circulating and synovial 
mononuclear cells of RA patients are already stimulated by many inflammatory stimuli, histamine and its immu-
nologic response could be down-regulated in RA local synovial environment.
Histamine induced osteoclast differentiation from its potential precursors, CD14+ monocytes, in the pres-
ence of M-CSF. There are two possible mechanisms in histamine-induced osteoclastogenesis. First, histamine 
directly induced osteoclastogenesis, independent of RANKL stimulation. Second, histamine stimulated the 
monocytes and other synovial cells to express RANKL, and then they were differentiated into mature osteoclasts 
with RANKL produced by autocrine and paracrine effects. There is controversy in the role of histamine in auto-
immune diseases, it is not confirmed whether it has anti-inflammatory or pro-inflammatory role. In this study, 
histamine has definite osteoclastogenic role through RANKL induction and direct induction of osteoclast differ-
entiation, mediating by H4R.
As well as histamine, IL-6 and Th17 family cytokines, IL-17, IL-21 and IL-22, stimulated H4R expression. 
Especially IL-21 and IL-22 had stronger effect for H4R stimulation than histamine. The Th17 cytokines strongly 
induced RANKL expression and this effect was mediated through H4R. This result is consistent with the in vivo 
study that treatment with H4R antagonist reduces the number of IL-17 positive cells in the lymph nodes29. It 
is already known that IL-17, IL-21 and IL-22 have osteoclastogenic role in RA pathogenesis39, 40. In our recent 
study, they stimulate RANKL expression and directly induce osteoclast differentiation and synovial fibroblasts 
which are exposed by Th17 cytokines also induces osteoclastogenesis41. H4R is directly stimulated by Th17 
cytokines and H4R antagonist reduced the Th17 cytokine-induced osteoclast differentiation. This result suggests 
Th17 cytokine-induced H4R expression could be another mechanism for osteoclastogenesis induced by these 
cytokines. As well as their unique receptors, Th17 cytokines could augment the osteoclastogenesis via additional 
stimulation for another inflammatory receptor, H4R. Among the Th17 cytokines, IL-17 and IL-22 had strong 
effect for the induction of H4R and RANKL expression and the differentiation into osteoclasts among three 
cytokines, so IL-22 or IL-17/H4R axis could be potential therapeutic target for RA-associated bone destruction. 
Because this study did not investigate the role of IL-6 in H4R-mediated osteoclastogenesis, IL-6 would be further 
investigated in this area.
There was phase II clinical study of toreforant, a novel, orally active, selective H4R antagonist, in patients with 
active RA despite MTX therapy. Although toreforant 100 mg/day improved DAS28-CRP and ACR20 response 
in 12 weeks, the phase IIa study terminated prematurely because of fatal adverse effect of hemophagocytic lym-
phohistiocytosis. In phase IIb study reduced the dose of toreforant because of the fatal adverse effect. In the 
reduced doses, there was no significant improvement in DAS28-CRP in week 1242. Insufficient doses with short 
duration showed no significant result, so circumstantial study for the relationship of the drug and adverse effect 
should indicate appropriate doses and study duration. Moreover, other H4R antagonists with different antagonis-
tic mechanisms would be further developed.
Histamine concentration and H4R expression in PB monocytes were increased in RA patients. H4R could play 
a major role in bone destruction of RA, by mediating RANKL expression and osteoclast differentiations which is 
induced by histamine and Th17 cytokines. The inhibition of the linkage between H4R and Th17 cytokines could 
be a new therapeutic option for preventing bone destruction in RA.
Methods
Ethics Statement and Patients. Written informed consent was obtained from patients with RA and oste-
oarthritis and healthy volunteers. All RA patients fulfilled the 1987 revised criteria of the American College of 
Rheumatology (ACR)43. SF was obtained from 3 RA patients (age 56.7 ± 12.7 years, 1 male and 2 females, dis-
ease duration 6.8 ± 1.1 years, erythrocyte sedimentation rate (ESR) 46.7 ± 36.2 mm/h, C-reactive protein (CRP) 
3.5 ± 3.3 mg/dl) and 3 patients with knee osteoarthritis (age 70.3 ± 1.3 year, all females). All SF was obtained by 
therapeutic arthrocentesis before steroid injection into swollen joints. Peripheral blood (PB) was obtained from 
3 RA patients (age 53.7 ± 4.8 years, disease duration 1.1 ± 0.5 years, ESR 47.0 ± 18.3 mm/h, CRP 0.7 ± 0.7 mg/dl) 
and healthy volunteers. All methods were performed in accordance with the relevant guidelines and regulations. 
Written informed consent was obtained from patients with RA and osteoarthritis and healthy volunteers. The 
protocol for this study was approved by Institutional Review Board for Human Research in Konkuk University 
Hospital.
Reagents. Recombinant TNF-α, IL-1β, IL-6, IL-17, IL-21, IL-22 and IL-23 were purchased from R&D sys-
tems (Minneapolis, MN, USA). Histamine and a H4R antagonist, JNJ7777120, were purchased from the Sigma 
Chemical Co. (St Louis, MA, USA).
www.nature.com/scientificreports/
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ELISA for measuring SF and serum concentration of histamine. SF was obtained from patients with 
RA and osteoarthritis. Serum was obtained from patients with RA and healthy volunteers. SF and serum were 
measured for histamine content by Histamin ELISA kit according to the manufacturer’s instructions (Enzo Life 
Sciences Inc., NY, USA).
Expression of H4R mRNA by reverse transcription–polymerase chain reaction (RT-PCR). PB 
and SF monocytes were incubated with various concentrations of histamine and cytokines in the presence or 
absence of JNJ7777120. After 16 hours of incubation, mRNA was extracted with RNAzol B (Biotex Laboratories, 
Houston, TX, USA) in accordance with the manufacturer’s instructions. Reverse transcription of 2 μg of total 
mRNA was performed at 42 °C using the Superscript™ reverse transcription system (Takara, Shiga, Japan). PCR 
amplification of cDNA aliquots was performed by adding 2.5 mM dNTPs, 2.5 U of Taq DNA polymerase (Takara) 
and 0.25 μM of sense and antisense primers. The reaction was performed in PCR buffer (1.5 mM MgCl2, 50 mM 
KCl, 10 mM Tris-HCl, pH 8.3) in a total volume of 25 μl. Reactions were processed in a DNA thermal cycler 
(Perkin- Elmer Cetus, Norwalk, CT, USA) through cycles for 30 seconds of denaturation at 94 °C, 1 min of anneal-
ing at 60 °C (β-actin) or 59 °C (H4r), followed by 1 min of elongation at 72 °C. PCR rounds were repeated for 25 
cycles each for H4r and beta-actin; this was determined as falling within the exponential phase of amplification 
for each molecule. The level of mRNA expression was presented as a ratio of Target PCR product over beta-actin 
product.
Real-time PCR for quantitation of H4R and RANKL mRNA. mRNA was extracted using RNAzol 
B according to the instructions of the manufacturer (Biotex). Reverse transcription of total mRNA (2 μg) was 
performed at 42 °C using a SuperScript RT system (Takara). PCR was performed in a final volume of 20 μl in 
capillary tubes in a LightCycler (Roche Diagnostics). The reaction mixture contained 2 μl LightCycler FastStart 
DNAMaster Mix for SYBR Green I (Roche Diagnostics), 0.5 μM of each primer, 4 mM MgCl2, and 2 μl of template 
DNA. All of the capillaries were amplified in a LightCycler instrument with activation of polymerase (95 °C for 
10 minute), followed by 45 cycles of 10 seconds at 95 °C, 10 seconds at 60 °C (beta-actin) or 59 °C (H4r, Rankl, 
Trap, Rank, Ctr, Mmp-9), and 10 seconds at 72 °C. The temperature transition rate was 20 °C/second for all steps. 
The following sense and antisense primers for each molecules were used: H4r sense, 5′-GGA AGC GTG ATC 
ATC TCA GTA GGT-3′; H4r antisense, 5′-TCT GAA TGA GTG TCC ACG ATG TT-3′; Rankl sense, 5′-ACC 
AGC ATC AAA ATC CCA AG-3′; Rankl antisense, 5′-CCC CAA AGT ATG TTG CAT CC-3′; Trap sense, 
5′-GAC CAC CTT GGC AAT GTC TCT G-3′; Trap antisense, 5′-TGG CTG AGG AAG TCA TCT GAG TTG-3′; 
Rank sense, 5′-GCT CTA ACA AAT GTG AAC CAG GA-3′; Rank antisense, 5′-GCC TTG CCT GTA TCA CAA 
ACT-3′; Cathepsin K sense, 5′-TGA GGC TTC TCT TGG TGT CCA TAC-3′; Cathepsin K antisense, 5′-AAA 
GGG TGT CAT TAC TGC GGG-3′; Mmp-9 sense, 5′-CGC AGA CAT CGT CAT CCA GT-3′; Mmp-9 antisense, 
5′-GGA TTG GCC TTG GAA GAT GA-3′; Calcitonin receptor sense, 5′-TGG TGC CAA CCA CTA TCC ATG 
C-3′; Calcitonin receptor antisense, 5′-CAC AAG TGC CGC CAT GAC AG-3′; beta-actin sense, 5′-GGA CTT 
CGA GCA AGA GAT GG-3′; beta-actin antisense, 5′-TGT GTT GGC GAT CAG GTC TTT- G-3′. Melting curve 
analysis was performed immediately after the amplification protocol, under the following conditions: 0 seconds 
(hold time) at 95 °C, 15 seconds at 71 °C, and 0 seconds (hold time) at 95 °C. The rate of temperature change was 
20 °C/second except in the final step, during which it was 0.1 °C/second. The melting peak generated represented 
the quantity of specific amplified product. The crossing point was defined as the maximum of the second deriva-
tive from the fluorescence curve. Negative controls that contained all elements of the reaction mixture except for 
the template DNA were also included. All samples were processed in duplicate.
Monocyte isolation and osteoclast differentiation. PBMCs and SFMCs were separated and washed 
three times with sterile PBS and resuspended in RPMI 1640 (Life Technologies, Grand Island, NY, USA) sup-
plemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1% penicillin-streptomycin, henceforth 
called complete medium. Freshly isolated PBMCs and SFMCs were incubated at 37 °C in complete medium and 
allowed to adhere for 45 minutes. The non-adherent cells were removed and the adherent cells were washed with 
sterile PBS, harvested with a rubber policeman, and stained with the monocyte-specific anti-CD14 monoclonal 
antibody to assess the purity of the preparation. Ninety percent of the isolated cells were monocytes expressing 
CD14. The osteoclast precursors were prepared using the monocytes-enriched fraction from PB. The cells were 
co-cultured for 3 weeks in minimal essential medium (MEM)-α and 10% heat-inactivated FBS in the presence 
of 25 ng/ml rhM-CSF and histamine/Th17 cytokines/JNJ7777120. The medium was changed on day 3 and then 
every other day thereafter. On day 21, tartrate-resistant acid phosphatase (TRAP)-positive cells were identified 
using a leukocyte acid phosphatase kit according to the manufacturer’s protocol (Sigma-Aldrich).
Statistical analysis. Results are expressed as mean ± standard error of the mean (SEM). Statistical dif-
ferences were assessed using Mann-Whitney U test for analyzing two groups or one-way analysis of variance 
(ANOVA) with Bonferroni’s multiple comparison post-hoc test for analyzing more than three groups. A P 
value < 0.05 was considered statistically significant.
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